EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and safety of diazepam nasal spray in Japanese Pediatric patients with or at risk for status epilepticus: a phase 3, Multicenter, open-label clinical trial

Eiji Nakagawa, Jun Tohyama, Ryutaro Kira, Mitsugu Uematsu, Shin Okazaki, Hideaki Shiraishi, Kazuhiro Muramatsu, Kazuya Itomi, Junichi Onuma, Shinichiro Takeuchi, Kikuo Tsukahara, Katsumi Imai

Epilepsy & Behavior Reports · 2026-12 · 36 · 100898

DOI: 10.1016/j.ebr.2026.100898 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsy & Behavior Reports, 2026-12. Verfasst von Eiji Nakagawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Center of Neurology and Psychiatry, Tokyo, Japan. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of diazepam nasal spray (tradename: SPYDIA in Japan, VALTOCO® in the US) following single (Part 1) and multiple (Part 2) dose administrations in pediatric epilepsy patients.

Methods

Patients aged 6-17 years with status epilepticus (SE) or at risk for progression to SE despite stable antiseizure medication were eligible. In Part 1, a single intranasal dose (5, 10, or 15 mg) was administered immediately after the onset of a prespecified convulsive seizure. The primary endpoint was the responder rate (seizures ceasing within 10 min post-dose without recurrence for 30 min) in this part. In Part 2, multiple doses were administered for up to 24 weeks to assess efficacy and safety.

Results

From November 2022 and January 2024, 22 participants were enrolled in Part 1; 16 were treated. The responder rate was 62.5% (10/16; 95% CI, 35.4-84.8), with the lower CI limit exceeding the 30% threshold. In Part 2, 14 participants treated 91 seizures; 71.4% ceased within 10 min without recurrence for 12 h. Overall, 18 participants received diazepam nasal spray; 14 (77.8%) experienced treatment-emergent adverse events (TEAEs). No TEAEs led to discontinuation, and all treatment-related TEAEs were mild. Treatment satisfaction ("very" or "fairly" satisfied) was reported by 15/16 (93.8%) and 15/17 (88.2%) participants in Parts 1 and 2, respectively.

Conclusion

These findings support the favorable efficacy and safety profiles of diazepam nasal spray as a rescue therapy in pediatric patients with or at risk for SE.

Schlagwörter

Stichwörter der Autor:innen

Clinical trialDiazepam nasal sprayEpilepsyRescue medicationStatus epilepticus

Autor:innen und Institutionen

  • National Center of Neurology and Psychiatry, Tokyo, Japan.
  • National Hospital Organization Nishiniigata Chuo Hospital, Niigata, Japan.
  • Fukuoka Children's Hospital, Fukuoka, Japan.
  • Tohoku University School of Medicine, Miyagi, Japan.
  • Osaka City General Hospital, Osaka, Japan.
  • Dokkyo Medical University, Tochigi, Japan.

Zitieren

APA

Nakagawa, E., Tohyama, J., Kira, R., Uematsu, M., Okazaki, S., Shiraishi, H., Muramatsu, K., Itomi, K., Onuma, J., Takeuchi, S., Tsukahara, K., & Imai, K. (2026). Efficacy and safety of diazepam nasal spray in Japanese Pediatric patients with or at risk for status epilepticus: a phase 3, Multicenter, open-label clinical trial. Epilepsy & Behavior Reports, 36, 100898. https://doi.org/10.1016/j.ebr.2026.100898

Vancouver

Nakagawa E, Tohyama J, Kira R, Uematsu M, Okazaki S, Shiraishi H, et al. Efficacy and safety of diazepam nasal spray in Japanese Pediatric patients with or at risk for status epilepticus: a phase 3, Multicenter, open-label clinical trial. Epilepsy & Behavior Reports. 2026;36:100898. doi:10.1016/j.ebr.2026.100898

BibTeX
@article{Nakagawa2026,
  author = {Nakagawa, Eiji and Tohyama, Jun and Kira, Ryutaro and Uematsu, Mitsugu and Okazaki, Shin and Shiraishi, Hideaki and Muramatsu, Kazuhiro and Itomi, Kazuya and Onuma, Junichi and Takeuchi, Shinichiro and Tsukahara, Kikuo and Imai, Katsumi},
  title = {Efficacy and safety of diazepam nasal spray in Japanese Pediatric patients with or at risk for status epilepticus: a phase 3, Multicenter, open-label clinical trial},
  journal = {Epilepsy & Behavior Reports},
  year = {2026},
  volume = {36},
  pages = {100898},
  doi = {10.1016/j.ebr.2026.100898}
}
Kostenlos starten →